SCHEMBL1296191

SCHEMBL1296191

COC(=O)C[C@@H](CC(=O)CC(=O)OCc1ccccc1)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.42
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ATM Q13315 1/20 0.38
SLC15A1 P46059 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ABCC3 O15438 1/20 0.36
NR1I2 O75469 1/20 0.36
ABCB11 O95342 1/20 0.36
NR3C1 P04150 1/20 0.36
RARG P13631 1/20 0.36
CNR1 P21554 1/20 0.36
OPRK1 P41145 1/20 0.36
NR1H2 P55055 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1296194 1.00 ABCB1 (0.42) ABCB1ALDH1A1MAPK1L3MBTL1ATM
SCHEMBL16245288 0.82 SLC15A1 (0.44) ABCB1ALDH1A1MAPK1L3MBTL1ATM
SCHEMBL21383918 0.82 HTT (0.46) ABCB1L3MBTL1ATMHTTSMN1; SMN2
SCHEMBL12567292 0.81 KCNA5 (0.32) ALDH1A1
SCHEMBL18196801 0.80 ALDH1A1 (0.42) ABCB1ALDH1A1MAPK1L3MBTL1ATM
SCHEMBL1295495 0.79 TSHR (0.30)
SCHEMBL1295490 0.79 TSHR (0.30)
SCHEMBL8301377 0.79 ABCB1 (0.45) ABCB1ALDH1A1MAPK1L3MBTL1ATM
SCHEMBL21383920 0.78 HTT (0.44) ABCB1L3MBTL1ATMHTTSMN1; SMN2
SCHEMBL15653580 0.77 TSHR (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269962-A1 PROCESS FOR PREPARING STATINS DIPHARMA FRANCIS S.R.L. (IT) 2011-11-03 US disclosed
EP-2383260-A2 Process for the preparation of statins Dipharma Francis S.r.l. (IT) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269962-A1 PROCESS FOR PREPARING STATINS HMGCR, CYP51A1, PCSK9 ABCB1 1240/4885ALDH1A1 3699/4885MAPK1 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.